Key late-stage drugs projected to hit market in '23

Citeline has recently published the Key Potential Drug Launches in 2023 report sharing insights on a longer-term outlook of some key late-stage drugs projected to hit the market in 2023.

These drugs represent new drug classes, major changes to standards of care, and large market opportunities across the globe.

Here are a few key potential drug launches: Chronic Heart Failure (CHF) remains a key area of attention for drug makers. In this scenario, Furoscix is a reformulation of the diuretic furosemide which has been developed for the treatment of decompensated heart failure and designed to be self-administered in the outpatient setting through a subcutaneous infusion via a wearable, on-body drug delivery system. It will be used to treat worsening heart failure, due to congestion, in patients with New York Heart Association class II and class III chronic heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization.